Trends in Integrated Delivery Networks and Pharma Partnerships

This white paper discusses the evolving landscape of Integrated Delivery Networks (IDNs) and their implications for pharmaceutical companies. It outlines the findings from interviews with key decision-makers in advanced healthcare systems and market access leaders from pharmaceutical companies. The paper identifies significant trends affecting IDNs, including pricing pressures, the transition to value-based care, and marketplace competition. It details how IDNs are responding to these challenges through service line extensions, population health initiatives, and value-based risk agreements. The document emphasizes the importance of partnerships between IDNs and pharmaceutical organizations, highlighting the need for early engagement and a collaborative approach to address shared goals. It also notes that traditional sales methods are becoming less effective, necessitating a shift in how pharma engages with IDNs. The paper concludes by presenting examples of therapeutic areas where partnerships are being formed, illustrating the evolving nature of these collaborations.